{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:27:50Z","timestamp":1773815270745,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00280-013-2319-2","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T03:21:56Z","timestamp":1382584916000},"page":"79-86","source":"Crossref","is-referenced-by-count":39,"title":["Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies"],"prefix":"10.1007","volume":"73","author":[{"given":"Wei-qun","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin-hua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-yuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"2319_CR1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0929-6646(10)60123-4","volume":"109","author":"CH Pui","year":"2010","unstructured":"Pui CH (2010) Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 109:777\u2013787","journal-title":"J Formos Med Assoc"},{"key":"2319_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/028418698429586","volume":"37","author":"C Rask","year":"1998","unstructured":"Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C (1998) Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia\u2013a logistic regression analysis. Acta Oncol 37:277\u2013284","journal-title":"Acta Oncol"},{"key":"2319_CR3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","volume":"12","author":"MV Relling","year":"1994","unstructured":"Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667\u20131672","journal-title":"J Clin Oncol"},{"key":"2319_CR4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MPH.0b013e31814d6777","volume":"29","author":"W Xu","year":"2007","unstructured":"Xu W, Tang Y, Song H, Shi S, Yang S (2007) Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol 29:688\u2013693","journal-title":"J Pediatr Hematol Oncol"},{"key":"2319_CR5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/02841869509094036","volume":"34","author":"M Takami","year":"1995","unstructured":"Takami M, Kuniyoshi Y, Oomukai T, Ishida T, Yamano Y (1995) Severe complications after high-dose methotrexate treatment. Acta Oncol 34:611\u2013612","journal-title":"Acta Oncol"},{"key":"2319_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00252984","volume":"19","author":"JD Borsi","year":"1987","unstructured":"Borsi JD, Revesz T, Schuler D (1987) Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 19:261\u2013264","journal-title":"Cancer Chemother Pharmacol"},{"key":"2319_CR7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.1989.7.10.1539","volume":"7","author":"B Camitta","year":"1989","unstructured":"Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, Civin C, Graham M, Mahoney D, Munoz L et al (1989) Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 7:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"2319_CR8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0145-2126(96)00127-0","volume":"21","author":"H Seidel","year":"1997","unstructured":"Seidel H, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slordal L (1997) On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia. Leuk Res 21:429\u2013434","journal-title":"Leuk Res"},{"key":"2319_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","volume":"72","author":"JL Pauley","year":"2013","unstructured":"Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro R, Rubnitz J, Pui CH, Evans WE, Relling MV (2013) Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72:369\u2013378","journal-title":"Cancer Chemother Pharmacol"},{"key":"2319_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FTD.0b013e318203b41e","volume":"33","author":"E Dombrowsky","year":"2011","unstructured":"Dombrowsky E, Jayaraman B, Narayan M, Barrett JS (2011) Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit 33:99\u2013107","journal-title":"Ther Drug Monit"},{"key":"2319_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/pbc.24081","volume":"59","author":"G Kapoor","year":"2012","unstructured":"Kapoor G, Sinha R, Abedin S (2012) Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer 59:448\u2013453","journal-title":"Pediatr Blood Cancer"},{"key":"2319_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","volume":"51","author":"T Skarby","year":"2003","unstructured":"Skarby T, Jonsson P, Hjorth L, Behrentz M, Bjork O, Forestier E, Jarfelt M, Lonnerholm G, Hoglund P (2003) High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 51:311\u2013320","journal-title":"Cancer Chemother Pharmacol"},{"key":"2319_CR13","volume-title":"Principles and practice of pediatric oncology","author":"PA Pizzo","year":"2006","unstructured":"Pizzo PA, Poplack DG (2006) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, Philadelphia"},{"key":"2319_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","volume":"33","author":"K Fukuhara","year":"2008","unstructured":"Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33:677\u2013684","journal-title":"J Clin Pharm Ther"},{"key":"2319_CR15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/pbc.21629","volume":"51","author":"Y Tang","year":"2008","unstructured":"Tang Y, Xu X, Song H, Yang S, Shi S, Wei J (2008) Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer 51:380\u2013386","journal-title":"Pediatr Blood Cancer"},{"key":"2319_CR16","first-page":"385","volume":"22","author":"H Ye","year":"2001","unstructured":"Ye H, Gu L, Chen J (2001) High-dose methotrexate therapy in children with acute lymphoblastic leukemia. Chin J Hematol 22:385\u2013386","journal-title":"Chin J Hematol"},{"key":"2319_CR17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mpo.10293","volume":"40","author":"L Hempel","year":"2003","unstructured":"Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, Rost M, Zintl F (2003) Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40:348\u2013354","journal-title":"Med Pediatr Oncol"},{"key":"2319_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(84)90411-2","volume":"1","author":"WE Evans","year":"1984","unstructured":"Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1:359\u2013362","journal-title":"Lancet"},{"key":"2319_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20032","volume":"43","author":"P Joannon","year":"2004","unstructured":"Joannon P, Oviedo I, Campbell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43:17\u201322","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2319-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2319-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:14:39Z","timestamp":1596734079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2319-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2319-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}